BMS-986251
selective RORgt inverse agonist entered clinical dev. (psoriasis), discontinued from HTS and SBDD ACS Med. Chem. Lett., Apr. 10, 2020 Bristol Myers Squibb, Princeton, NJ
Molecules of the Month - April 2020
Molecules of the Month
- tucatinib
- S6821
- MRTX849
- BAY1161909
- ORN0829
- BMS-986251
- GSK2818713
- CPI-1612
- “Compound 19”
- AZD4205
- QPX7728
- “Compound 9”
- “Compound (P)-14″
- FT385